Using Fluorescence-Based Sensing to Accelerate Process Development - A prove-free system monitors accurately at very small scale - BioPharm International

ADVERTISEMENT

Using Fluorescence-Based Sensing to Accelerate Process Development
A prove-free system monitors accurately at very small scale


BioPharm International
Volume 22, Issue 6

ABSTRACT

Bioprocesses have long been ubiquitous in the production of modern pharmaceuticals and drugs. Contemporary bioprocesses are being increasingly used in the production of many other products, ranging from biodegradable plastics, packing materials, and other throwaways, to non-fossil fuels such as ethanol and biodiesel, and commonly needed human spare parts such as artificial skin and cartilage. Fluorescence-based sensing technologies, which can greatly decrease overall development time, labor, and costs, become an increasingly useful tool, particularly because their use permits a degree of miniaturization, scalability, and multiplexing that was previously unavailable.


(New Brunswick Scientific)
Partly because of the growing number of applications, in the last few decades "faster, better, cheaper" has driven advances in bioprocess techniques in much the same way that it has driven advances in electronics, medical care, and other competitive industries. Even minor technological improvements in the early screening stages of drug discovery can improve speed to market and increase profits. Improvements in the pilot and production stages of development lead to reduced production costs that, for a long-lived drug (the ideal goal of any such development endeavor), can lead to increased profits over the longterm.

The initial stages of a bioprocess development cycle, whether for a drug or other product, typically require an enormous number of experiments (thousands or even tens of thousands) to select an optimal cell line and media formulation. Even then, the cell line and formulation selected is merely the best of those tested. The more combinations tested, the better the chance that the combination selected will be close to optimal.

These experiments must be done quickly to minimize development time. This requirement mandates that the experiments be done, to the extent possible, in parallel. Until recently, this initial screening was done almost exclusively in well plates or flasks, vessels that were reasonably inexpensive and thus economically feasible for a high degree of parallelism. However, these systems run mostly blind, with little or no instrumentation to track and control relevant process parameters.

Typically, the only data available to the research scientist are the results of offline measurements, which are labor intensive to take and produce results of questionable accuracy because process parameters are subject to measurable change during the sampling process. Consequently, little data are obtained regarding optimal process parameters; process optimization is generally left to be done heuristically in bioreactors. The latter systems are adequately instrumented and capable of measuring and controlling salient process parameters. However, because of the discrete and expensive nature of experiments run in such systems, a fairly limited number of experiments may be performed in an attempt to determine what constitutes optimal culture conditions. Even small errors in what are determined to be (in contrast to what actually are) optimal conditions can result in enormous increases in production costs over time. In addition, if the range of allowable variances in such conditions is not adequately explored and documented, the possibility exists that valuable and viable batches of product may be discarded because of small excursions from so-called ideal culturing conditions, even though the excursions may actually be of little consequence.


Figure 1
Process parameters are needed even during the screening stages of development. This is illustrated in Figure 1, which shows an experiment performed with E. coli in a 50-mL flask. As shown, the dissolved oxygen (DO) level reaches its minimum (and hence the cell line its viable maximum) just three hours into the run. Commonly, such an experiment would be started in a flask, which would then be left to continue overnight without interruption until morning. Offline sampling at that point in time would be misleading because it would show only the end of run conditions and provide no information as to what actually transpired during the run.

Of course, small laboratory-scale bioreactors could be used for the initial screening of cell lines and media as well as for process optimization. However, purchasing large numbers of individual bioreactors for the screening stage would be prohibitively expensive and setting up, running, breaking down, and cleaning a large number of such bioreactors would require an enormous amount of labor. If bioreactors were to be used, the degree of parallelism (and hence the number of experiments performed in a given period of time) would be quite limited or else the time required for the initial stages of the development cycle would increase dramatically.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here